Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Unithroid Misappropriated Trade Secrets Claims Against FDA Reinstated

This article was originally published in The Pink Sheet Daily

Executive Summary

Federal appeals court rules Jerome Stevens properly alleged an independent injury resulting from FDA’s disclosure of trade secrets and confidential information relating to the Unithroid (levothyroxine) NDA.

You may also be interested in...

Levothyroxine Bioequivalence To Be Discussed At FDA Public Meeting

Scheduling the event suggests FDA is re-evaluating its position on the interchangeability of the drug class. Announcement of the May 23 meeting comes nearly one year after the agency approved a number of equivalence claims for levothyroxine sodium products.

Endpoint Milestone In AML: Kronos’ Entospletinib Trial Will Rely On Residual Disease

Phase III study in newly diagnosed patients with NPM1-mutated AML could enable Kronos’ SYK-inhibitor to reach market two years earlier under accelerated approval than it would under a traditional endpoint, company says.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts